Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/epzZCduTtWCinoAfCidncVCicNiBeE
- Roche, Isis ally to develop Huntington's disease drugs
Roche Holding and Isis Pharmaceuticals agreed to collaborate in the development of Huntington's disease drugs using the latter's antisense technology. The partners will initially focus on Isis' lead drug candidate designed to inhibit production of all forms of a protein involved in the genetic brain disorder. Isis will get $30 million upfront and as much as $362 million in licensing and milestone fees plus sales royalties on drugs arising from the collaboration. Yahoo/Reuters (4/8)        | Complimentary White Paper: Improving Total Cost of Ownership with EQMS
Companies are looking for ways to improve product quality, customer satisfaction and profitability while dealing with rising costs, competition and regulatory pressures. This white paper details how utilizing an EQMS backbone enables a broader organizational view of these issues, allowing for increased revenues and margins, operational efficiencies and global standardization for stakeholders. Read it now! | |
| Health Care & Policy |  |  | | - Sunshine rules coming in 2014 for doctors, drugmakers
The public will gain access beginning in September 2014 to records of payments that drugmakers make to doctors. The disclosures currently planned by the CMS may not provide enough context for the public to understand that large payments that support research don't simply go into a doctor's pocket, one expert said. Arkansas Business (4/8) | Company & Financial News | | | | | Global Developments | | | | | Food & Agriculture | | | | - Spending-bill provision won't protect biotech firms like critics say
 The hysteria over a biotech crop provision signed into law last month has no basis because there's no truth to critics' claims about the law, Bloomberg View columnist Ramesh Ponnuru writes. The law's real impact is modest, and it would permit farmers to continue using products that are safe in case of frivolous lawsuits, Ponnuru writes. Bloomberg (4/8) | Industrial & Environmental | | | | - BIO, others support reconsideration of 2012 cellulosic goal
BIO and other members of the Biofuels Producers Coordinating Council said they support the Environmental Protection Agency's implementation of a court order to reconsider the 2012 cellulosic biofuel target under the Renewable Fuel Standard. "We look forward to working with EPA to establish 2013 targets that are consistent with expected production volumes this year from the facilities that have already been built," the council said. DomesticFuel.com (4/8) | News from BIO | | | | - Evidence, Coverage and Incentives: A PMC/BIO Solutions Summit
BIO and the Personalized Medicine Coalition have partnered to bring together all stakeholders to discuss potential solutions to advance personalized medicine on April 17 in Washington, D.C. A key focus of the summit is a determination of the nature and level of evidence necessary to make reliable and appropriate decisions on the coverage, regulation and adoption of personalized medicine products. Other topics to be addressed are market access issues for companion diagnostics and incentives for the development of personalized medicine products. Learn more and register.
| SmartQuote | | | |  | Saints are sinners who kept on going."
--Robert Louis Stevenson,
Scottish novelist, poet and essayist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, April 08, 2013
- Friday, April 05, 2013
- Thursday, April 04, 2013
- Wednesday, April 03, 2013
- Tuesday, April 02, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment